Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.

The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.

[1]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[2]  Frederick J. Schoen,et al.  Early In Vivo Experience With Tissue-Engineered Trileaflet Heart Valves , 2000, Circulation.

[3]  Therapy Study Investigators.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure , 1993, The Lancet.

[4]  T. Pedersen,et al.  Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. , 1997, Journal of the American College of Cardiology.

[5]  Sonia S Anand,et al.  Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. , 1999, JAMA.

[6]  W. J. Maclntyre,et al.  Prognosis of Patients With Left Ventricular Dysfunction, With and Without Viable Myocardium After Myocardial Infarction: Relative Efficacy of Medical Therapy and Revascularization , 1994, Circulation.

[7]  H. Tunstall-Pedoe,et al.  Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. , 1999, Lancet.

[8]  P. Epstein.  Cholera and the environment , 1992, The Lancet.

[9]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[10]  Eric Boersma,et al.  Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.

[11]  W. Fennell,et al.  Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. , 1998, Journal of the American College of Cardiology.

[12]  J. Denollet,et al.  Reducing Emotional Distress Improves Prognosis in Coronary Heart Disease: 9-Year Mortality in a Clinical Trial of Rehabilitation , 2001, Circulation.

[13]  Wojciech Zareba,et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. , 2002, The New England journal of medicine.

[14]  G. Uijen,et al.  Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial , 2002, Circulation.

[15]  E. Topol,et al.  Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. , 1994, Circulation.

[16]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[17]  W. Dassen,et al.  Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study , 1999, Heart.

[18]  H. White,et al.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. , 1999, The New England journal of medicine.

[19]  R. Collins,et al.  Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO) , 1997 .

[20]  L. Morrison,et al.  Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. , 2000, JAMA.

[21]  A. Maggioni,et al.  Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. , 1997, Circulation.

[22]  J. Reiber,et al.  A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. , 1993, The New England journal of medicine.

[23]  J P Roos,et al.  Prognostic Value of Exercise Testing, Coronary Angiography and Left Ventriculography 6–8 Weeks After Myocardial Infarction , 1982, Circulation.

[24]  P. Armstrong,et al.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. , 2001 .

[25]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[26]  H. Arendrup,et al.  Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. , 1997, Circulation.

[27]  U. Tebbe,et al.  Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.

[28]  Grace Investigators,et al.  Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. , 2001, American heart journal.

[29]  J. F. Dammann,et al.  The significance of the pulmonary vascular bed in congenital heart disease. I. Normal lungs. II. Malformations of the heart in which there is pulmonary stenosis. , 1956, American heart journal.

[30]  M. Simoons,et al.  A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. , 1997, The New England journal of medicine.

[31]  D. Singer,et al.  Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. , 2000, Circulation.

[32]  J. Denollet,et al.  Personality, disease severity, and the risk of long-term cardiac events in patients with a decreased ejection fraction after myocardial infarction. , 1998, Circulation.

[33]  H. Yki-Järvinen.  Pathogenesis of non-insulin-dependent diabetes mellitus , 1994, The Lancet.

[34]  S. Fletcher,et al.  Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) , 1992, The Lancet.

[35]  M. de Lorgeril,et al.  Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. , 1999, Circulation.

[36]  R. Dietz,et al.  Effect of captopril and lisinopril on circadian blood pressure rhythm and renal function in mild-to-moderate heart failure. , 1992, The American journal of cardiology.

[37]  L. Wallentin,et al.  The low‐molecular‐weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study , 2001, Clinical cardiology.

[38]  G. Specchia,et al.  Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. , 2000, European heart journal.

[39]  T. Killip,et al.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. , 1967, The American journal of cardiology.

[40]  M L Simoons,et al.  A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). , 2002, European heart journal.

[41]  H. Heidbuchel,et al.  Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial , 2002, Circulation.

[42]  M. Motro,et al.  Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.

[43]  M. Simoons.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.

[44]  Jean-Louis Martin,et al.  Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction Final Report of the Lyon Diet Heart Study , 1999 .

[45]  P Smith,et al.  The effect of warfarin on mortality and reinfarction after myocardial infarction. , 1990, The New England journal of medicine.

[46]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[47]  H A Feldman,et al.  Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial. , 2000, JAMA.

[48]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[49]  David Hunt,et al.  ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .

[50]  J. Buring,et al.  An overview of randomized trials of rehabilitation with exercise after myocardial infarction. , 1989, Circulation.

[51]  F. Verheugt.  A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. , 1997, The New England journal of medicine.

[52]  C. Taylor,et al.  Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. , 1990, Annals of internal medicine.

[53]  P. Thompson,et al.  Impact of a national educational campaign to reduce patient delay in possible heart attack. , 1993, Australian and New Zealand journal of medicine.

[54]  O Parodi,et al.  The impact of myocardial blood flow quantitation with PET on the understanding of cardiac diseases. , 1996, European heart journal.

[55]  R. Giugliano,et al.  A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. , 1999, Journal of the American College of Cardiology.

[56]  E. Holme,et al.  Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. , 1999, European heart journal.

[57]  J. Mlczoch,et al.  Early diagnosis of subacute free wall rupture complicating acute myocardial infarction. , 1993, European heart journal.

[58]  O. Topaz,et al.  Interventricular septal rupture complicating acute myocardial infarction: from pathophysiologic features to the role of invasive and noninvasive diagnostic modalities in current management. , 1992, The American journal of medicine.

[59]  R O Bonow,et al.  Identification of viable myocardium. , 1996, Circulation.

[60]  M. Lengyel,et al.  Long-term survival of post-infarction free wall rupture without operation. , 1996, European heart journal.

[61]  M. Davies.  The pathophysiology of acute coronary syndromes , 2000, Indian heart journal.

[62]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[63]  F. Van de Werf,et al.  The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. , 1992, The New England journal of medicine.

[64]  M. Schwaiger,et al.  Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. , 2000, The New England journal of medicine.

[65]  Long-term comprehensive care of cardiac patients. Recommendations by the Working Group on Rehabilitation of the European Society of Cardiology. , 1992, European heart journal.

[66]  G. Stone,et al.  Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. , 2000, The New England journal of medicine.

[67]  M. Pfeffer,et al.  When a question has an answer: rationale for our early termination of the HEART Trial. , 1995, The American journal of cardiology.

[68]  E. Braunwald,et al.  Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II , 1992, Circulation.

[69]  S. Greenhouse,et al.  A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial , 1999 .

[70]  J. Rawles,et al.  Earliest electrocardiographic evidence of myocardial infarction: implications for thrombolytic treatment. The GREAT Group. , 1993, BMJ.

[71]  S. Greenhouse,et al.  A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. , 1999, Journal of the American College of Cardiology.

[72]  P. Sellier.  Angina pectoris in patients with a history of myocardial infarction. , 1996, European heart journal.

[73]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[74]  P. Touboul,et al.  Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study , 2002, The Lancet.

[75]  Gusto Angiographic Investigators.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[76]  F. Van de Werf,et al.  Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up. , 1995, Circulation.

[77]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[78]  R. Califf,et al.  Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. , 1998, Journal of the American College of Cardiology.

[79]  R. Wilcox,et al.  Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence International Joint Efficacy Comparison of Thrombolytics , 1995, The Lancet.

[80]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[81]  A. Tajik,et al.  Papillary muscle rupture complicating acute myocardial infarction: analysis of 17 patients. , 1983, The American journal of cardiology.

[82]  R. Califf,et al.  Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. , 1995, Circulation.

[83]  Y. Ohtsuki,et al.  ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.

[84]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[85]  GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. , 1994, Lancet.

[86]  C. Peterson.  A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: Grines CL, Browne KF, Marco J, et al. N Engl J Med 328:673–679 Mar 1993 , 1993 .

[87]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[88]  J O'Keefe,et al.  A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .

[89]  M. Ezekowitz,et al.  Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial Infarction: Primary Results of the CHAMP Study , 2002, Circulation.

[90]  F. Van de Werf,et al.  Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. , 1993, Journal of the American College of Cardiology.

[91]  R. Califf,et al.  A clinical comparison of mitral valve repair versus valve replacement in ischemic mitral regurgitation. , 1988, The Journal of thoracic and cardiovascular surgery.

[92]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .

[93]  E. Topol.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. , 2001, Lancet.

[94]  H. Arnesen,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[95]  A. Tonkin,et al.  A Randomized Comparison of Intravenous Heparin With Oral Aspirin and Dipyridamole 24 Hours After Recombinant Tissue‐Type Plasminogen Activator for Acute Myocardial Infarction , 1991, Circulation.

[96]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[97]  D. Faxon,et al.  Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. , 1993, Journal of the American College of Cardiology.

[98]  M J Davies,et al.  The pathophysiology of acute coronary syndromes , 2000, Heart.

[99]  R. Collins,et al.  Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1) , 1995, The Lancet.

[100]  L. Tavazzi,et al.  Prevalence and Prognostic Significance of Ventricular Arrhythmias After Acute Myocardial Infarction in the Fibrinolytic Era GISSI‐2 Results , 1993, Circulation.

[101]  J. W. Kinch,et al.  Right ventricular infarction. , 1994, The New England journal of medicine.

[102]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[103]  M. Hadamitzky,et al.  Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. , 2000, Journal of the American College of Cardiology.

[104]  R Peto,et al.  Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. , 1991, BMJ.

[105]  K. Beatt,et al.  Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. , 1997, Circulation.

[106]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[107]  A. Maggioni,et al.  Prognostic significance of maximal exercise testing after myocardial infarction treated with thrombolytic agents: the GISSI-2 data-base , 1995, The Lancet.

[108]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[109]  T. Böhm,et al.  Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. , 1997, European heart journal.

[110]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[111]  C. Cannon,et al.  A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. , 1994, Journal of the American College of Cardiology.

[112]  J. Burchenal,et al.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. , 1998, Circulation.

[113]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[114]  C. Furberg,et al.  Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. , 1991, The American journal of cardiology.

[115]  T. Investigators,et al.  A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .

[116]  W. Boden,et al.  Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial , 2000, The Lancet.

[117]  N. Powe,et al.  Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. , 2000, Circulation.

[118]  R. Califf,et al.  Individual risk assessment for intracranial haemorrhage during thrombolytic therapy , 1993, The Lancet.

[119]  J. López-Sendón,et al.  Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria. , 1992, Journal of the American College of Cardiology.

[120]  K. Malmberg.  Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[121]  L. Johansson,et al.  Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2-7 year follow-up. , 1988, European heart journal.

[122]  F. Werf.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[123]  E. Antman.  Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.

[124]  M. Simoons,et al.  Prehospital thrombolysis with alteplase (rt-PA) in acute myocardial infarction. , 1992, European heart journal.

[125]  M L Simoons,et al.  Estimated gain in life expectancy. A simple tool to select optimal reperfusion treatment in individual patients with evolving myocardial infarction. , 1996, European heart journal.

[126]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[127]  D. Grobbee,et al.  Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial , 2002, The Lancet.

[128]  R. O'rourke,et al.  Physical examination for exclusion of hemodynamically important right ventricular infarction. , 1983, Annals of internal medicine.

[129]  C. Fry,et al.  Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.

[130]  R. Campbell,et al.  Amiodarone in the management of atrial fibrillation complicating myocardial infarction. , 1986, British journal of clinical practice. Supplement.

[131]  M. Kornitzer,et al.  The ESPRIM trial - short-term treatment of acute myocardial-infarction with molsidomine. , 1994 .

[132]  E. Antman,et al.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.

[133]  C. Bode,et al.  Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial , 2001, The Lancet.

[134]  Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. , 1992, BMJ.

[135]  J. Hsia,et al.  A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.

[136]  K. Lee,et al.  Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. , 1997, Circulation.

[137]  European Cooperative Study Group.  The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine , 1994, The Lancet.

[138]  J. Deanfield.  Treatment effects on the total ischaemic burden and prognostic implications. , 1996, European heart journal.

[139]  Coumadin Aspirin Reinfarction Study Investigators.  Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction , 1997, The Lancet.

[140]  T D Miller,et al.  Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction. , 2000, Circulation.

[141]  B. Gersh,et al.  Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. , 1992, The American journal of cardiology.

[142]  K. Wegscheider,et al.  Effects of thrombolytic therapy in acute inferior myocardial infarction with or without right ventricular involvement. HIT-4 Trial Group. Hirudin for Improvement of Thrombolysis. , 1998, Journal of the American College of Cardiology.

[143]  W. O’Neill,et al.  Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. , 1991, Annals of internal medicine.

[144]  W. H. Kern,et al.  Perforation of the interventricular septum complicating myocardial infarction , 1956 .

[145]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[146]  K. Coyne,et al.  Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin: Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II) , 2001, Circulation.

[147]  K. Bailey,et al.  Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. , 1993, The New England journal of medicine.

[148]  K. Lee,et al.  Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. , 1996, Circulation.

[149]  Eli Warnock,et al.  The effect of diltiazem on mortality and reinfarction after myocardial infarction. , 1989, The New England journal of medicine.

[150]  S. Iliceto,et al.  Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications. , 1996, European heart journal.

[151]  SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. , 1991, BMJ.

[152]  R. Norris,et al.  Prognosis after myocardial infarction. Six-year follow-up. , 1974, British heart journal.

[153]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[154]  P. Armstrong,et al.  Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. , 1996, European heart journal.

[155]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[156]  T. Pedersen.  Six-year follow-up of the Norwegian multicenter study on timolol after myocardial infarction. , 1986 .

[157]  D. Ketley,et al.  Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction , 1993, The Lancet.

[158]  R M Norris,et al.  Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. , 1998, BMJ.

[159]  N Freemantle,et al.  beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.

[160]  Norris Rm,et al.  Fatality outside hospital from acute coronary events in three British health districts, 1994-5 , 1998 .

[161]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[162]  H. White,et al.  One-year survival following early revascularization for cardiogenic shock. , 2001, JAMA.

[163]  H. Tunstall-Pedoe,et al.  Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations , 1999, The Lancet.

[164]  S. Roux,et al.  Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. , 1992, Journal of the American College of Cardiology.

[165]  R. Collins,et al.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.

[166]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[167]  M. Verani,et al.  Role of adenosine thallium-201 tomography for defining long-term risk in patients after acute myocardial infarction. , 1995, Journal of the American College of Cardiology.

[168]  K. Swedberg,et al.  Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.

[169]  U. Tebbe,et al.  Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. , 1999, American heart journal.

[170]  R. Collins,et al.  Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. , 1988, JAMA.

[171]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. , 1995, The New England journal of medicine.

[172]  R. Califf,et al.  Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction , 1997 .

[173]  L. Rydén,et al.  Improved physical fitness and quality of life following training of elderly patients after acute coronary events. A 1 year follow-up randomized controlled study. , 1999, European heart journal.

[174]  R. Hendel,et al.  Clinical value of acute rest technetium-99m tetrofosmin tomographic myocardial perfusion imaging in patients with acute chest pain and nondiagnostic electrocardiograms. , 1998, Journal of the American College of Cardiology.

[175]  M. H. Phillips,et al.  Changes in cardiorespiratory fitness, psychological wellbeing, quality of life, and vocational status following a 12 month cardiac exercise rehabilitation programme , 1999 .

[176]  M. Lengyel.  The Role of Transesophageal Echocardiography in the Management of Patients with Acute and Chronic Pulmonary Thromboembolism , 1995, Echocardiography.

[177]  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. , 1989, The New England journal of medicine.

[178]  M. Turina,et al.  Postinfarction ventricular septal defect--surgical strategies and results. , 1989, The Thoracic and cardiovascular surgeon.

[179]  W. Dassen,et al.  Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. , 1990, Journal of the American College of Cardiology.

[180]  S. Gellis,et al.  Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. , 1991 .

[181]  J. Murgo,et al.  Knowledge of perfusion and contractile reserve improves the predictive value of recovery of regional myocardial function postrevascularization: a study using the combination of myocardial contrast echocardiography and dobutamine echocardiography. , 1997, Circulation.

[182]  S. Johansson,et al.  Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. , 1983, British heart journal.

[183]  E. Gilpin,et al.  Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. , 1988, The American journal of cardiology.

[184]  T. Pedersen.  Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. , 1985, The New England journal of medicine.

[185]  H. Krumholz,et al.  Thrombolytic therapy in older patients. , 2000, Journal of the American College of Cardiology.

[186]  K. Lee,et al.  A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.

[187]  R. Califf,et al.  Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. , 1996, Journal of the American College of Cardiology.

[188]  Assent investigators.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.

[189]  M. Joy.  Introduction and summary of principal conclusions to the first European workshop in aviation cardiology. , 1992, European heart journal.

[190]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[191]  F. Van de Werf,et al.  Thrombolysis for acute myocardial infarction. , 1998, Circulation.

[192]  W. Rogers,et al.  Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. , 1991, Circulation.

[193]  J. J. Griffin,et al.  Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. , 2002, The New England journal of medicine.

[194]  P. Marino,et al.  Prognostic value of detection of myocardial viability using low-dose dobutamine echocardiography in infarcted patients. , 1998, The American journal of cardiology.

[195]  J P Ornato,et al.  Comprehensive strategy for the evaluation and triage of the chest pain patient. , 1997, Annals of emergency medicine.

[196]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[197]  M. Pfisterer,et al.  Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. , 1992, British heart journal.

[198]  R. Gibbons,et al.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction : A quantitative review , 1997 .

[199]  Nie Fe.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II) , 1990 .

[200]  R. Wilcox.  Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence: International Joint Efficacy Comparison of Thrombolytics , 1995 .

[201]  E. Antman,et al.  Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. , 2001, American heart journal.

[202]  O'Rourke Ra.  Treatment of right ventricular infarction: thrombolytic therapy, coronary angioplasty or neither? , 1998 .

[203]  Bruce R. Brodie,et al.  Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction , 1999 .

[204]  J. Burchenal,et al.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. , 1998, Circulation.

[205]  J. Dimarco.  Results from late-breaking clinical trials sessions at ACC 2001 , 2001 .

[206]  A. Kitabatake,et al.  Lack of Myocardial Perfusion Immediately After Successful Thrombolysis: A Predictor of Poor Recovery of Left Ventricular Function in Anterior Myocardial Infarction , 1992, Circulation.

[207]  U Keil,et al.  The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. , 2000, European heart journal.

[208]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[209]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[210]  H. Wellens,et al.  Lidocaine in the prevention of primary ventricular fibrillation , 2000 .

[211]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[212]  P. Rigo,et al.  Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. , 1990, Journal of the American College of Cardiology.

[213]  M. Trevisan,et al.  Results of a multicenter randomized clinical trial of exercise and long-term survival in myocardial infarction patients: the National Exercise and Heart Disease Project (NEHDP). , 1999, Circulation.

[214]  C. Gamallo,et al.  Anatomic findings in acute papillary muscle necrosis. , 1989, American heart journal.

[215]  J. Kostis,et al.  Rapid hemodynamic improvement in right ventricular infarction after coronary angioplasty. , 1988, Chest.

[216]  R W Koster,et al.  Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. , 1985, The New England journal of medicine.

[217]  W. Fennell,et al.  Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. , 1998, Journal of the American College of Cardiology.

[218]  H. White.  Thrombolytic therapy in the elderly , 2000, The Lancet.

[219]  Anticoagulants in the Secondary Prevention of Events in Coronary Group.  Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction , 1994, The Lancet.

[220]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[221]  B. Brodie,et al.  Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy. , 1991, The American journal of cardiology.

[222]  E. Falk.  Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. , 1985, Circulation.

[223]  S. Yusuf,et al.  Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[224]  J. Cleland.  Preventing atherosclerotic events with aspirin , 2002, BMJ : British Medical Journal.

[225]  J. Ottervanger,et al.  Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. , 1999, The New England journal of medicine.

[226]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.

[227]  J Herlitz,et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.

[228]  P. Kudenchuk,et al.  Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. , 1993, JAMA.

[229]  E. Topol,et al.  Recognition of the importance of embolization in atherosclerotic vascular disease. , 2000, Circulation.

[230]  W. Rogers,et al.  The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. , 2000, The New England journal of medicine.

[231]  L. Køber,et al.  Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. , 1999, Lancet.

[232]  H. White,et al.  Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial , 2001, The Lancet.

[233]  J. Tcheng.  Primary angioplasty in acute myocardial infarction , 2002 .

[234]  L. Wallentin,et al.  Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.

[235]  K. Donald,et al.  Natural history of acute coronary heart attacks. A community study. , 1972, British heart journal.

[236]  D. Julian,et al.  Treatable arrhythmias in cardiac arrests seen outside hospital , 1992, The Lancet.

[237]  R. Califf,et al.  Evaluation of Combination Thrombolytic Therapy and Timing of Cardiac Catheterization in Acute Myocardial Infarction: Results of Thrombolysis and Angioplasty in Myocardial Infarction–Phase5 Randomized Trial , 1991, Circulation.

[238]  M. L. Simoons,et al.  Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction: the AMI-SK study☆ , 2003 .

[239]  K. Lee,et al.  Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.

[240]  S. Kaul.  Myocardial contrast echocardiography in acute myocardial infarction. , 1992, American journal of cardiac imaging.

[241]  A. Siegbahn,et al.  Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). , 1999, Journal of the American College of Cardiology.

[242]  A. Piwnica.  Update in surgical treatment of acute post infarction VSDs and MIs. , 1995, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[243]  R. Collins,et al.  Effect of Intravenous Nitrates on Mortality in Acute Myocardial Infarction , 1993 .

[244]  B. Gersh,et al.  Mechanical and electrical complications of acute myocardial infarction. , 1990, Mayo Clinic proceedings.

[245]  InTIME-II Investigators,et al.  Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. , 2000, European heart journal.

[246]  P. Elwood,et al.  EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART) , 1989, The Lancet.

[247]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[248]  P. Barragan,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction , 2001 .

[249]  G. Timmis,et al.  Sequence of mechanical, electrocardiographic and clinical effects of repeated coronary artery occlusion in human beings: echocardiographic observations during coronary angioplasty. , 1985, Journal of the American College of Cardiology.

[250]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[251]  J. Herlitz,et al.  A media campaign aiming at reducing delay times and increasing the use of ambulance in AMI. , 1994, The American journal of emergency medicine.

[252]  J. Tijssen,et al.  Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. , 1989, Journal of the American College of Cardiology.

[253]  M. Mariani,et al.  Correlates of survival in patients with postinfarction ventricular septal defect. , 1998, The Annals of thoracic surgery.

[254]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[255]  M L Simoons,et al.  Pre-hospital triage of patients with suspected myocardial infarction. Evaluation of previously developed algorithms and new proposals. , 1995, European heart journal.

[256]  B. Davis,et al.  Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. , 1999, Journal of the American College of Cardiology.

[257]  L. Køber,et al.  Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarction , 1999, The Lancet.

[258]  S. Pocock,et al.  A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial , 1996, BMJ.

[259]  R. Califf,et al.  Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology. , 2000, Journal of the American College of Cardiology.

[260]  R. Collins,et al.  Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. , 1997, Circulation.

[261]  C. Gray.  The way I see it: Being more formal and cultivating gravitas may make you a better doctor , 2002 .